BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 15370671)

  • 1. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
    Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
    Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
    Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
    Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation: results of a Spanish multicenter study.
    de la Rubia J; Montesinos P; Martino R; Jarque I; Rovira M; Vázquez L; López J; Batlle M; de la Cámara R; Juliá A; Lahuerta JJ; Debén G; Díaz J; García R; Sanz MA
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):512-6. PubMed ID: 19285640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients.
    Miller JA; Butler T; Beveridge RA; Kales AN; Binder RA; Smith LJ; Ueno WM; Milkovich G; Goldwater S; Marion A
    Clin Ther; 1993; 15(3):486-99. PubMed ID: 8364941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).
    Biron P; Fuhrmann C; Cure H; Viens P; Lefebvre D; Thyss A; Viot M; Soler-Michel P; Rollin C; Grès JJ
    J Antimicrob Chemother; 1998 Oct; 42(4):511-8. PubMed ID: 9818751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
    Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
    J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial.
    Kwon KT; Cheong HS; Rhee JY; Wi YM; Ryu SY; Heo ST; Moon CS; Ki HK; Kim KH; Jung CW; Peck KR; Song JH
    Jpn J Clin Oncol; 2008 Jan; 38(1):49-55. PubMed ID: 18203711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes].
    Figuera A; Tomás JF; Hernández L; Jiménez ML; Peñarrubia MJ; del Rey MC; Arranz R; Cámara R; López-Lorenzo JL; Fernández-Rañada JM
    Rev Clin Esp; 1996 Aug; 196(8):515-22. PubMed ID: 8984537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors.
    Kebudi R; Görgün O; Ayan I; Gürler N; Akici F; Töreci K
    Med Pediatr Oncol; 2001 Apr; 36(4):434-41. PubMed ID: 11260566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How should imipenem-cilastatin be used in the treatment of fever and infection in neutropenic cancer patients?
    Raad II; Abi-Said D; Rolston KV; Karl CL; Bodey GP
    Cancer; 1998 Jun; 82(12):2449-58. PubMed ID: 9635539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
    Pérez C; Sirham M; Labarca J; Grebe G; Lira P; Oliva J; Duhalde M; Ocqueteau M; Acuña G
    Rev Med Chil; 1995 Mar; 123(3):312-20. PubMed ID: 8525170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study.
    Slobbe L; Waal Lv; Jongman LR; Lugtenburg PJ; Rijnders BJ
    Eur J Cancer; 2009 Nov; 45(16):2810-7. PubMed ID: 19647995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefepime monotherapy for treatment of febrile neutropenia in children.
    Ariffin H; Ai CL; Lee CL; Abdullah WA
    J Paediatr Child Health; 2006 Dec; 42(12):781-4. PubMed ID: 17096713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study.
    Norrby SR; Vandercam B; Louie T; Runde V; Norberg B; Anniko M; Andrien F; Baudrihaye M; Bow E; Burman LA
    Scand J Infect Dis Suppl; 1987; 52():65-78. PubMed ID: 3331044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of febrile neutropenia episodes in systemic hematologic illnesses with new once daily ceftriaxone administration].
    Karthaus M; Südhoff T; Fenchel K; Egerer G; Kämpfe D; Ritter J; Franke A; Heil G; Peters G; Jürgens H
    Wien Med Wochenschr; 1998; 148(21):481-7. PubMed ID: 10048176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study.
    Böhme A; Shah PM; Stille W; Hoelzer D
    Eur J Med Res; 1998 Jul; 3(7):324-30. PubMed ID: 9682028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
    Hamidah A; Lim YS; Zulkifli SZ; Zarina AL; Nordiah AJ; Jamal R
    Singapore Med J; 2007 Jul; 48(7):615-9. PubMed ID: 17609821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized monocentric trial in febrile neutropenic patients: ceftriaxone and gentamicin vs cefepime and gentamicin.
    Cornely OA; Bethe U; Seifert H; Breuer K; Schütt-Gerowitt H; Salzberger B; Schrappe M; Fätkenheuer G
    Ann Hematol; 2002 Jan; 81(1):37-43. PubMed ID: 11807634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
    Sanz MA; Bermúdez A; Rovira M; Besalduch J; Pascual MJ; Nocea G; Sanz-Rodríguez C;
    Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study.
    Tamura K; Matsuoka H; Tsukada J; Masuda M; Ikeda S; Matsuishi E; Kawano F; Izumi Y; Uike N; Utsunomiya A; Saburi Y; Shibuya T; Imamura Y; Hanada S; Okamura S; Gondoh H;
    Am J Hematol; 2002 Dec; 71(4):248-55. PubMed ID: 12447952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.